5 Recruiting Studies Using Idelalisib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Idelalisib
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
📍 Research Site — Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Recurrent Chronic Lymphoid Leukemia
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Southern Cancer Center, P.C. — Daphne, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔ 🟢 Recruiting Phase4 💊 Investigational Drug / Biologic
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
📍 Mitchell Cancer Institute — Mobile, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔ 🟢 Recruiting Phase3 💊 Investigational Drug / Biologic
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
📍 St Bernards Medical Center — Jonesboro, Arkansas
CLL
View Study & Checklist ➔